Abstract
Hibiscetin, as one of the main bioactive constituents of Hibiscus sabdariffa, has many pharmacological activities, but its antihyperglycemic activity has not been fully interpreted yet. The current research was developed from this perspective. The study intended to appraise the antidiabetic capability of hibiscetin in a high-fat diet (HFD) and streptozotocin (STZ; 50 mg/kg, intraperitoneally)-induced diabetes in an experimental animal. The efficiency of hibiscetin at 10 mg/kg in an "HFD/STZ model" remedy in rats with experimentally caused diabetes was explored for 42 days. The efficacy of hibiscetin was observed on several diabetes parameters. The average body weight and an array of biochemical markers were determined, including blood glucose, insulin, total protein (TP), lipid profile, aspartate aminotransferase (AST), alanine aminotransferase (ALT), IL-6, IL-1 beta, tumor necrosis factor-alpha (TNF-alpha), adiponectin, leptin, resistin, malondialdehyde (MDA), catalase (CAT), glutathione (GSH), and superoxide dismutase (SOD). The antidiabetic benefits of hibiscetin were proven by a substantial reduction in blood glucose, lipid profile (TC and TG), total protein, IL-6, IL-1 beta, MDA, TNF-alpha, leptin, adiponectin, ALT, and AST in the therapy group compared to the diabetic disease standard. Furthermore, hibiscetin therapy also reversed the lowered levels of insulin, resistin, GSH, SOD, and CAT in diabetic rats. It was determined that hibiscetin may be beneficial in terms of reducing diabetes problems due to its effects on both oxidative stress and inflammation and that more research for this design should be conducted.